BMS的PD-1明星单抗Opdivo引领其第二季度销售额达57亿美元

2018-07-27 MedSci MedSci原创

BMS在第二季度中,几乎所有的主要产品都超过销售预期,销售额达57亿美元,这一数字超过市场预期的54.8亿美元。每股收益达到1.01美元,打破了华尔街87美分的预测。

默沙东MSD的PD-1单抗Keytruda在肺癌治疗中取得的巨大成功,让投资者对百时美施贵宝BMS在该领域的未来而担心。BMS的肺癌治疗管线也正在全力以赴去争取市场份额。

BMS在第二季度中,几乎所有的主要产品都超过销售预期,销售额达57亿美元,这一数字超过市场预期的54.8亿美元。每股收益达到1.01美元,打破了华尔街87美分的预测。

这一局面主要是由BMS的大型抗癌药物引领,肿瘤免疫抑制剂 PD-1抗体Opdivo创造了16.3亿美元的收入,超过预测的14.6亿美元。Opdivo的巨大销售额得益于该药物在二线肺癌市场占有领先地位,保持着30%-35%市场份额。但随着竞争对手MSD的Keytruda获批, Opdivo市场份额也有所降低。

BMS首席财务官Charlie Bancroft在公司第二季度电话会议上表示,Opdivo在黑色素瘤和肾癌中表现也促进了BMS整体销售额的上升。 Opdivo和Yervoy(CTLA-4单抗)的联合用药在新诊断的肾癌患者中已经占有30%的份额。与此同时,Yervoy的销量也有所增加,季度销售额达3.15亿美元,远超于预期的5700万美元。

原始出处:


此文系梅斯医学(MedSci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687313, encodeId=b807168e313a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Apr 15 19:12:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303069, encodeId=0e4d1303069be, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378655, encodeId=9fe713e865519, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379914, encodeId=d1f713e99140c, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687313, encodeId=b807168e313a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Apr 15 19:12:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303069, encodeId=0e4d1303069be, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378655, encodeId=9fe713e865519, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379914, encodeId=d1f713e99140c, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-07-29 119337457
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687313, encodeId=b807168e313a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Apr 15 19:12:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303069, encodeId=0e4d1303069be, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378655, encodeId=9fe713e865519, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379914, encodeId=d1f713e99140c, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-07-29 canlab
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687313, encodeId=b807168e313a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Apr 15 19:12:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303069, encodeId=0e4d1303069be, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378655, encodeId=9fe713e865519, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379914, encodeId=d1f713e99140c, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Sun Jul 29 01:12:00 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-07-29 zxl729

相关资讯

Blood:霍奇金淋巴瘤肿瘤微环境中,CD4+效应T细胞耗竭、调节T细胞富集

中心点:新确诊的原发性cHLs伴随CD4+Th1极化调节T细胞和分化的效应T细胞增多。原发性cHLs表现出两种主要的免疫抑制互补——PD-1+Th1效应细胞耗竭和PD-1-Th1调节T细胞活化。摘要:经典型霍奇金淋巴瘤(cHL)患者抗肿瘤免疫反应失效。霍奇金RS(HRS)细胞有多种逃脱免疫细胞的机制,包括9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2)遗传变异、PD-1配体过

CLIN CANCER RES:CD103+肿瘤定植CD8+T细胞与黑色素瘤患者接受抗PD-1治疗预后改善有关

免疫检查点抑制疗法为肿瘤治疗带来了革命。但是只有不到一半的接受治疗的患者出现持续缓解。由于缺少对启动抗肿瘤免疫反应的细胞特征的理解,如何改善治疗效果也一直并不明确。CLIN CANCER RES近期发表了一篇文章研究这一问题。

Nat Immunol:PD-1/PD-L1不响应机制被揭密,NK细胞其核心作用

本周二,国际顶级期刊《自然免疫学》刊登了中国科学技术大学田志刚、孙汭(rui)教授课题组的重要研究成果[2]。他们的研究成果在一定程度上解释了为什么有些患者对目前的免疫检查点抑制剂治疗不响应;更重要的是,他们的研究成果有望大幅扩大免疫检查点抑制剂适用的患者群体。本研究的第一作者是张清博士。 伴随研究论文同期发表的评论性文章给予该研究非常高的评价,“检查点抑制剂:自然杀伤(

Cell Rep:大开眼界!肿瘤细胞竟是这样躲过免疫治疗的!

目前,以PD-1/PD-L1抑制剂为主的免疫疗法已成为肿瘤治疗领域的绝对热门,但是,PD-1 /PD-L1抑制剂在不同类型肿瘤病人中应用后,其效果却因人而异。科学家们曾认为这是受制于患者肿瘤细胞PD-L1的表达水平,然而,随着对PD-1 /PD-L1抑制剂疗法的深入研究,研究人员发现部分患者即使表达了高水平的PD-L1,PD-1 /PD-L1抑制剂仍无法有效治疗肿瘤。这是为什么呢?

百济神州公布其PD-1抗体Tislelizumab治疗霍奇金淋巴瘤中的关键性临床试验初步结果

百济神州Biogene(纳斯达克股票代码:BGNE)是一家处于商业阶段的生物医药公司,专注于开发和商业化治疗癌症的创新分子靶向药物和肿瘤免疫药物。近日公司公布了其PD-1抗体Tslelizumab治疗复发/难治性经典霍奇金淋巴瘤(R/R cHL)中国患者的关键性2期临床试验独立审查的初步结果。

PD-1单抗Keytruda单一疗法显著延长头颈癌患者生存期

默沙东(MSD)的Keytruda作为单一疗法,用于PD-L1阳性的复发或转移性头颈部鳞状细胞癌(HNSCC)患者的一线治疗时,显着延长了患者的总体存活率。